Clearance Summary
Simplexa COVID-19 & Flu A/B Direct received FDA 510(k) clearance under submission number K220963, sponsored by Diasorin Molecular, LLC. The device was reviewed via the Traditional premarket notification pathway and assigned to the Microbiology review panel. The statutory decision date of record is 2023-03-17.
- Submission: K220963
- Applicant / Sponsor: Diasorin Molecular, LLC
- Clearance pathway: Traditional
- Review panel: Microbiology
- Device class: Class II
- Regulation citation: 21 CFR 866.3981
- Decision date: 2023-03-17
Classification & Regulation
This clearance is catalogued under FDA product code QOF and 21 CFR 866.3981, within the Microbiology review panel as a Class II device.